Celldex (CLDX) director James Marino awarded options on 26,000 shares
Rhea-AI Filing Summary
Celldex Therapeutics director James J. Marino received a grant of stock options as part of his equity compensation. He was awarded non-qualified options covering 26,000 shares of Common Stock, with an exercise price of $34.09 per share. The options were granted under Celldex’s 2021 Omnibus Equity Incentive Plan, carry no upfront cost to Marino, and are exercisable beginning on June 25, 2027. These options are scheduled to expire on June 25, 2036 if not exercised. After this grant, Marino holds options on 26,000 shares according to this filing.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
MARINO JAMES J
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Non-Qualified Stock Option (right to buy) | 26,000 | $0.00 | $0.00 |
Holdings After Transaction:
Non-Qualified Stock Option (right to buy) — 26,000 shares (Direct)
Footnotes (1)
- F1. Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan.
Key Figures
Options granted: 26,000 options
Underlying shares: 26,000 shares
Exercise price: $34.09 per share
+5 more
8 metrics
Options granted
26,000 options
Non-qualified stock option grant to director James J. Marino
Underlying shares
26,000 shares
Common Stock underlying the option grant
Exercise price
$34.09 per share
Strike price for the non-qualified stock options
Exercisable starting
June 25, 2027
Date options become exercisable
Expiration date
June 25, 2036
Date the options expire if unexercised
Post-grant option holdings
26,000 options
Total options held after this transaction per filing
Transaction code
A
Grant, award, or other acquisition of derivative security
Transaction date
June 25, 2026
Date of option grant
Key Terms
Non-Qualified Stock Option, 2021 Omnibus Equity Incentive Plan, Common Stock
3 terms
Non-Qualified Stock Option financial
"Non-Qualified Stock Option (right to buy)"
A non-qualified stock option (NSO) is a contract that lets an employee or service provider buy company shares at a fixed price for a set period, like a voucher to purchase stock later at today’s price. It matters to investors because exercising NSOs creates ordinary income for the holder and can increase share count, affecting a company’s earnings and ownership mix; think of it as a future sale that can dilute existing shareholders and has immediate tax consequences for the recipient.
2021 Omnibus Equity Incentive Plan financial
"Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan."
Common Stock financial
"underlying_security_title: Common Stock"
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What did Celldex Therapeutics (CLDX) director James J. Marino report on this Form 4?
James J. Marino reported receiving a grant of non-qualified stock options for 26,000 Celldex shares. The award is part of his equity compensation and does not represent an open-market purchase or sale of common stock.
What is the exercise price of James Marino’s Celldex (CLDX) stock options?
The options have an exercise price of $34.09 per share. This means Marino can buy Celldex common stock at $34.09 per share when he exercises the options, regardless of the market price at that time.
When can Marino begin exercising his Celldex (CLDX) stock options from this grant?
The options are exercisable beginning June 25, 2027. After that date, Marino may choose to exercise some or all of the 26,000 options any time before they expire, subject to the plan’s terms.
When do James Marino’s newly granted Celldex (CLDX) stock options expire?
The options expire on June 25, 2036 if they are not exercised. After that expiration date, Marino would no longer have the right to purchase Celldex shares at the fixed $34.09 exercise price from this grant.
Under which plan were James Marino’s Celldex (CLDX) options granted?
The options were granted under Celldex Therapeutics’ 2021 Omnibus Equity Incentive Plan. This plan authorizes the company to issue stock-based awards, such as options, to directors and other eligible participants as part of their compensation.